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Aims: 1-Compare regional LV LS between the 3 types of CA, 2 – Deter-
mine if they correlate to amyloid deposits; 3 – Determine the prognostic value
of LV LS.
Methods: 79 patients were prospectively included. 17 segments LV LS
was measured. 53 had cardiac MRI with LGE evaluation for each segment.
Amyloid deposition was quantified using Congo red staining in the
3 explanted heart following heart transplant (HT). All patients were followed-
up. The composite primary endpoint was major adverse cardiac event
(MACE) i.e., death, HT, and acute heart failure. MACE predictors were iden-
tified by multivariate analysis.
Results: 26 patients had AL, 36 m-TTR and 17 WT-TTR CA. Global
(–10±4%) and regional 17 LV LS were similarly impaired in the 3 types of
CA. 91% of MRI had LV LGE enhancement. Both LGE and LS analysis
showed a basal to apex gradient. Interestingly LS in the basal free wall (mean
– 5±6%) had the best accuracy to predict LGE (AUC=0.97, P=0.002; 95%CI
{0.92-0.99}). Amyloid deposits in the 3 HT were more frequent in the basal
segments and a strong correlation was found between LGE and LS segments
(r=0.72). 46% experienced MACE during the follow-up with median of
13[7;23] months for survivors. Apical LS, NT-proBNP and NYHA III-IV
were independently associated with MACE. Cut-off to predict MACE was
–14.5% for Apical LS and 4000ng/L for NT-proBNP.
Conclusions: LS abnormalities are similar between CA types and reflect
amyloid deposition which predominates in basal LV segments. Impairment of
basal free wall LS predict LV MRI LGE. High value of apical LS is an inde-
pendent predictor of MACE.
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Background: Accuracy of 99mTc-HMDP scintigraphy (sHMDP) to diag-
nose cardiac amyloidosis (CA) and to discriminate between the different eti-
ologies i.e hereditary TTR amyloidosis (hTTR), senile amyloidosis (wt-TTR)
and light chain amyloidosis (AL) are unknown.
Methods: 122 patients referred for suspected CA were prospectively
studied with sHMDP. HMDP fixation was evaluated by a visual score
(0 up to 3). Heart-to-whole-body (H/WB) and heart-to-skull (H/S) ratio
were calculated on planar images. Diagnosis of amyloidosis was biopsy
proven for all AL. Diagnosis of CA for hTTR and wt-TTR was established
by an experts consensus based on echocardiography, cardiac MRI (cardiac
wall thickness ≥12mm), genetic testing and biopsy whenever ethically
possible.
Results: The mean age was 69 (59; 78), 71% were men; of whom, 14
(11%) were considered having AL, 34 (28%) hTTR, 21 (17%) wt-TTR and 53
(43%) had cardiac hypertrophy from other causes. Of the 61 (50%) patients
with CA, 46 (75%) had a HMDP visual scoring ≥1; of whom 1/14 (7%) had
AL, 24/26 (92%) hTTR and 21/21 (100%) wt-TTR.
Cardiac HMPD uptake was absent among all patients without CA (n=61).
Visual score was stronger in TTR-CA versus AL-CA (p<0.0001). A visual
score ≥2 to diagnose TTR-CA had a predictive positive value of 100%.
Among CA, H/WB and H/S ratio were significantly higher (p <0.002) in both
hTTR (H/WB=3.92±0.93 H/S=2.26±0.98) and wt-TTR (H/WB=4.36±0.95 H/
S=2.86±1.12) versus AL (H/WB=2.67±0.61; H/S=1.70±1.53). Eleven patients
with myocardial 99mTc-HDPD uptake underwent a second sHMDP with a
median (25th; 75th) of 15.1 months (7.3; 16.2) of whom two had an increase in
visual score and H/WB ratio. (Image 1, next page) 
Conclusion: 99mTc-HMDP scintigraphy is a useful tool to diagnose CA,
define its etiology and might be useful for follow-up. 
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The incidence of sudden cardiac death (SCD) increases with age in parallel
with coronary’s diseases’ prevalence. In young persons and athletes, SCD
occurs in half of the cases, in the setting of genetically transmitted disorders
such as cardiomyopathies. Molecular testing performed after necropsy may
help management of families but experience in this area appears very limited.
The aim is to report our experience of post mortem molecular testing after
SCD and necropsy. We studied 36 patients <40 years who died suddenly with
a suspected diagnosis of cardiomyopathy, established either after autopsy or
known before death , with 6 dilated cardiomyopathy (DCM), 12 hypertrophic
(HCM), 2 HCM/DCM , 1 restrictive (CMR), 14 arrhythmogenic right ventric-
ular cardiomyopathy (ARVC), 1 HMC and left ventricular noncompaction.
Sanger sequencing was performed in most 4-5 frequent genes for a given phe-
notype. Fifteen mutations have been identified in sarcomeric (11 mutations) or
desmosomal (3 mutations) or lamin (1 mutation) genes. The identification of
these mutations had significant impact: assessing right diagnosis in a doubtful
case (HCM without LVH), modifying the appropriate diagnosis in another
case (HCM and not DCM), confirming a genetic disease even in the absence
of affected relatives in the family, providing guidance for genetic counselling
and predictive genetic testing in relatives in all situations. Technical, ethical
and legal issues may however be encountered and will be discussed. This
study is one of rare series of post-mortem molecular testing after SCD. Our
findings suggest the feasibility, molecular efficiency and the clinical benefit of
the approach in order to improve the management of families. Postmortem
molecular testing must take its place in the strategy of family care after SCD,
even if a cardiomyopathy is suspected at necropsy, since genetic findings pro-
vide additional information useful for the relatives. 
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This study was to assess features and outcomes of children with acute
myocarditis.
Methods: Patients <18y with acute myocarditis (proved by virology and/
or MRI and/ or complete recovery of myocardial function) were included.
Clinical data, echocardiographic parameters and outcomes were collected and
cases divided in groups I (< 2y), II (2 to 10y) and III (>10y). 
Results: 72 patients were included (1983 to 2012), 30males, aged 4.1±5.1y
(med1.5y): 43 in group I, 17 in II and 12 in III. Heart failure was present at
onset in 57(78%): 8 cardiogenic shock (12%), 30 severeHF (44%) were more
frequent in I (56%) and II (46%) than in III (17%, p< 0.0001), chest pain
(15.5%) was more frequent in III (83%). LVSF at diagnosis was 18.4±9%:
16% and 15% in groups I and II vs 30.5% in III (p= 0.0001). Aortic VTI was
11.4±5.8cm: 8cm and 11 in groups I and II vs 17 in group III (p< 0.05). Mitral
regurgitation was present in 76.5%, pericarditis in 16.4%, thromboembolic
events occurred in 5(7%), arrhythmias in 7(10%). Virus was found in
27=37.5% (1virus in 24, >in 3). Nine patients died (13%) within 2months
post-diagnosis (2days to 8.6months), 1 was transplanted (3rdmonth), 19 have
sequellae (27.5%), 40 recovered (58%), at FU= 5.5±5.6y. Inotrope was needed
in 34(47%):51%, 59% and 16% of groups I, II and III respectively
(p<0.0001). Six (8.3%, 1 in groupIII) needed mechanical circulatory support
(3ECMO, 3VAD), within day-14 from onset: 1 died on support, 5 were
